Affiliation:
1. Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, California
2. Chinook Therapeutics, Seattle, Washington
3. The VA Palo Alto Health Care System, Palo Alto, California
4. The Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, California
Abstract
ImportanceMetformin may have a protective association against developing osteoarthritis (OA), but robust epidemiological data are lacking.ObjectiveTo determine the risk of OA and joint replacement in individuals with type 2 diabetes treated with metformin compared with a sulfonylurea.Design, Setting, and ParticipantsThis retrospective cohort study used claims data from the Optum deidentified Clinformatics Data Mart Database between December 2003 and December 2019. Participants included individuals aged 40 years or older with at least 1 year of continuous enrollment and type 2 diabetes. Individuals with type 1 diabetes or a prior diagnosis of OA, inflammatory arthritis, or joint replacement were excluded. Time-conditional propensity score matching was conducted using age, sex, race, Charlson comorbidity score, and treatment duration to create a prevalent new-user cohort. Data were analyzed from April to December 2021.ExposuresTreatment with metformin or a sulfonylurea.Main Outcomes and MeasuresThe outcomes of interest were incident OA and joint replacement. Cox proportional hazard models were used to calculate adjusted hazard ratios (aHRs) of incident OA and joint replacement. In a sensitivity analysis, individuals only ever treated with metformin were compared with individuals only ever treated with a sulfonylurea, allowing for longer-term follow up of the outcome (even after stopping the medication of interest).ResultsAfter time-conditional propensity score matching, the metformin and control groups each included 20 937 individuals (mean [SD] age 62.0 [11.5] years; 24 379 [58.2%] males). In the adjusted analysis, the risk of developing OA was reduced by 24% for individuals treated with metformin compared with a sulfonylurea (aHR, 0.76; 95% CI, 0.68-0.85; P < .001), but there was no significant difference for risk of joint replacement (aHR, 0.80; 95% CI, 0.50-1.27; P = .34). In the sensitivity analysis, the risk of developing OA remained lower in individuals treated with metformin compared with a sulfonylurea (aHR, 0.77; 95% CI, 0.65-0.90; P < .001) and the risk of joint replacement remained not statistically significant (aHR, 1.04; 95% CI, 0.60-1.82; P = .89).Conclusions and RelevanceIn this cohort study of individuals with diabetes, metformin treatment was associated with a significant reduction in the risk of developing OA compared with sulfonylurea treatment. These results further support preclinical and observational data that suggest metformin may have a protective association against the development of OA; future interventional studies with metformin for the treatment or prevention of OA should be considered.
Publisher
American Medical Association (AMA)
Reference30 articles.
1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.;GBD 2017 Disease and Injury Incidence and Prevalence Collaborators;Lancet,2018
2. Osteoarthritis.;Hunter;Lancet,2019
3. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.;Foretz;Nat Rev Endocrinol,2019
4. Metformin in 2019.;Flory;JAMA,2019
5. Metformin and inflammation: its potential beyond glucose-lowering effect.;Saisho;Endocr Metab Immune Disord Drug Targets,2015
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献